Intestinal microsporidiosis: A hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?

Clinics

Volumn 66, Issue 7, 2011, Pages 1171-1175

  de Aikawa, Nadia Emi ^a   Twardowsky, Aline Oliveira ^a   de Carvalho, Jozélio Freire ^a   Silva, Clovis A ^a   França e Silva, Ivan Leonardo Avelino ^a   de Medeiros Ribeiro, Ana Cristina ^a   Saad, Carla Gonçalves Schain ^a   Moraes, Julio César Bertacini ^a   de Toledo, Roberto Acayaba ^b   Bonfá, Eloísa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

Author keywords

Ankylosing spondylitis; Anti TNF; Microsporidia; Parasitosis; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE CONTROL STUDY; DRUG ANTAGONISM; DRUG COMBINATION; ENTEROPATHY; FEMALE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MALE; MICROBIOLOGY; MICROSPORIDIOSIS; MIDDLE AGED; NONPARAMETRIC TEST; RHEUMATIC DISEASE; RISK FACTOR; SOCIOECONOMICS;

ADULT; ANTIRHEUMATIC AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL DISEASES; MALE; MICROSPORIDIOSIS; MIDDLE AGED; RHEUMATIC DISEASES; RISK FACTORS; SOCIOECONOMIC FACTORS; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052138193     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000700008     Document Type: Article

References (37)

1. Stark D, Barratt JL, van Hal S, Marriott D, Harkness J, Ellis JT. Clinical significance of enteric protozoa in the immunosuppressed human population. Clin Microbiol Rev. 2009;22:634-650, doi: 10.1128/CMR.00017-09.
2. Didier ES. Microsporidiosis: an emerging and opportunistic infection in humans and animals. Acta Trop. 2005;94:61-76, doi: 10.1016/j.actatropica.2005.01.010.
3. Didier ES, Weiss LM. Microsporidiosis: current status. Curr Opin Infect Dis. 2006;19:485-492, doi: 10.1097/01.qco.0000244055.46382.23.
4. Franzen C, Mller A. Cryptosporidia and microsporidia-waterborne diseases in the immunocompromised host. Diagn Microbiol Infect Dis. 1999;34:245-262, doi: 10.1016/S0732-8893(99)00003-6.
5. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factoralpha antagonists. Pharmacotherapy. 2005;25:1181-1192, doi: 10.1592/phco.2005.25.9.1181.
6. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritisuRheumatology. (Oxford) 2007;46:1157-1160, doi: 10.1093/rheumatology/kem076.
7. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39:327-346, doi: 10.1016/j.semarthrit.2008.10.002.
8. Krishnamurthy R, Dincer HE, Whittemore D. Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNFalpha therapy. J Clin Rheumatol. 2007;13:150-152, doi: 10.1097/RHU.0b013e3180690933.
9. Boatright MD, Wang BW. Clinical infection with Strongyloides sterocoralis following etanercept use for rheumatoid arthritis. Arthritis Rheum. 2005;52:1336-1337, doi: 10.1002/art.20882.
10. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-1602.
11. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-1411, doi: 10.1002/art.20217.
12. Punzi L, Podswiadek M, Sfriso P, Oliviero F, Fiocco U, Todesco S. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev. 2007;6:524-528, doi: 10.1016/j.autrev.2006.12.003.
13. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis.PediatricRheumatologyCollaborative StudyGroup. NEngl JMed.2000;342:763-769.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-314, doi: 10.1002/art.1780310302.
15. Bennett PH, Wood PHN. Population Studies of the Rheumatic Diseases. New York, Excerpta Medica. 1968, p 456.
16. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34:1218-1227, doi: 10.1002/art.1780341003.
17. Almeida PM, Wickerrhauser H. Critério de classe econômica da Associação Brasileira de Anunciantes (ABA) e Associação Brasileira dos Institutos de Pesquisa de Mercado (ABIPEME). 1991, pp 1-129.
18. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-48, doi: 10.1002/art.1780380107.
19. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286-2291.
20. Koga K, Kasuya S, Khamboonruang C, Sukavat K, Nakamura Y, Tani S, et al. An evaluation of the agar plate method for the detection of Strongyloides stercoralis in northern Thailand. J Trop Med Hyg. 1990;93:183-188.
21. Ryan NJ, Sutherland G, Coughlan K, Globan M, Doultree J, Marshall J, et al. A new trichrome-blue stain for detection of microsporidial species in urine, stool, and nasopharyngeal specimens. J Clin Microbiol. 1993;31:3264-3269.
22. Price DL. Comparison of three collection-preservation methods for detection of intestinal parasites. J Clin Microbiol. 1981;14:656-6560.
23. Henriksen SA, Pohlenz JF. Staining of cryptosporidia by a modified Ziehl-Neelsen technique. Acta Vet Scand. 1981;22:594-596.
24. Pereira DB Jr. Utilization of the Kato-Katz-method (thick-smear technique) the diagnosis of Isospora (author's transl). Rev Bras Pesqui Med Biol. 1979;12:351-352.
25. Oyarzabal OA, Macklin KS, Barbaree JM, Miller RS. Evaluation of agar plates for direct enumeration of Campylobacter spp. from poultry carcass rinses. Appl Environ Microbiol. 2005;71:3351-3354 doi: 10.1128/AEM.71.6.3351-3354.2005.
26. Farthing MJ. Treatment options for the eradication of intestinal protozoa. Nat Clin Pract Gastroenterol Hepatol. 2006;3:436-445 doi: 10.1038/ncpgasthep0557.
27. Chacin-Bonilla L, Panunzio AP, Monsalve-Castillo FM, Parra-Cepeda IE, Martinez R. Microsporidiosis in Venezuela: prevalence of intestinal microsporidiosis and its contribution to diarrhea in a group of human immunodeficiency virus-infected patients from Zulia State. Am J Trop Med Hyg. 2006;74:482-486.
28. Marangi A, Maggi P, Panaro MA, Angarano G, Pastore G, Lisi S, et al. Intestinal microsporidiosis in AIDS patients with diarrhoeal illness in Apulia (south Italy). New Microbiol. 1995;18:435-439.
29. Khan IA, Didier ES. Insights into the immune responses to microsporidia. In: Lindsay DS, Weiss LM. World Class Parasites. Vol. 9. Toxoplasma, sarcocystis, and microsporidia. Boston MA: Kluwer Academic Publishers. 2004. 135-157.
30. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci. 2004;1024:138-46, doi: 10.1196/annals.1321.010.
31. Galván AL, Agudelo Sdel P, Restrepo JG, Toro F, Galviz LA, Botero J. Cyclosporine A effect in mice C57BL/6 infected with Encephalitozoon intestinalis. Biomedica. 2006;26:126-137.
32. Jindal N, Arora S. Role of faecal leucocytes in the diagnostic evaluation of acute diarrhoea. Indian J Med Sci. 1991;45:261-264.
33. Gupta DN, Saha DR, Sengupta PG, Mondal SK, Ghosh S, Saha MR, et al. Value of faecal leucocyte count as an indicator of invasiveness in mucoid diarrhoea. J Commun Dis. 1997;29:329-332.
34. Haroon N, Inman RD. Infectious complications of biological therapy. Curr Opin Rheumatol. 2009;21:397-403, doi: 10.1097/BOR.0b013e32832c792d.
35. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39:327-346 doi: 10.1016/j.semarthrit.2008.10.002.
36. Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68:1863-1869, doi: 10.1136/ard.2008.102103.
37. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889-894, doi: 10.1136/ard.2005.043166.